The mechanisms exploited by marketed anti-obesity medicines are appetite suppression by increasing norepinephrine, dopamine, and serotonin in the synaptic clefts, pancreatic lipase, and amylase inhibition, and gastric emptying slowing. The gene discussed is PNLIP; the disease is Obesity.